U.S., April 7 -- ClinicalTrials.gov registry received information related to the study (NCT07512583) titled 'Clinical Studies of TQB2930 Injection for the Treatment of Advanced Solid Tumors' on March 25.
Brief Summary: This is a multicenter, open-label, multi-cohort phase Ib/II clinical study to evaluate the efficacy and safety of TQB2930 in combination with TQB2102 in patients with HER2-expressing advanced solid tumors.
Study Start Date: April, 2026
Study Type: INTERVENTIONAL
Condition:
Advanced Solid Tumor
Intervention:
DRUG: TQB2930 injection+TQB2102 for injection
TQB2930 Injection is a Human Epidermal Growth Factor Receptor 2 (HER2) bispecific antibody.
TQB2102 for injection is a HER2 - targeted dual epitope Antibody-Drug Conju...